Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 610 across all filing types
Latest filing 2023-03-24 Annual Report (ESEF)
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Annual Report (ESEF) 2022
Annual Report (ESEF) Classification · 1% confidence FY 2022
2023-03-24 Swedish
Alligator intends to carry out a 91 percent secured rights issue of units of approximately SEK 199 million
Share Issue/Capital Change Classification · 1% confidence The document is an announcement detailing a proposed '91 percent secured rights issue of units of approximately SEK 199 million' by Alligator Bioscience AB. It explicitly discusses subscription price, unit rights, warrants, subscription periods, shareholder undertakings, and guarantee commitments related to raising capital. This content directly aligns with the definition of a Capital/Financing Update. Although it mentions the upcoming publication of a Prospectus (which might suggest RPA), the core focus and the majority of the text detail the terms and structure of the financing event itself, making 'CAP' the most accurate classification over 'RPA' or 'RNS'. The document length is substantial (over 31k characters), indicating it is the primary announcement, not just a brief notice of publication.
2023-03-22 English
Alligator avser att genomföra en till 91 procent säkerställd företrädesemission av units om cirka 199 MSEK
Capital/Financing Update Classification · 1% confidence The document is a detailed press release announcing a rights issue ('Företrädesemission') of units (shares and warrants) intended to raise approximately 199 MSEK. It outlines the terms, subscription periods, shareholder voting requirements (extra general meeting), use of proceeds (funding clinical trials), and existing commitments (subscription undertakings and guarantee agreements). This content directly relates to capital structure changes and fundraising activities. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a proxy statement (PSI), but a specific announcement about raising capital.
2023-03-22 Swedish
Earnings Release 2022
Earnings Release Classification · 1% confidence The document contains key financial highlights for the period October - December 2022, including Net Sales, Operating Result, Net Result, and Earnings Per Share, comparing them to the previous year. It also includes a CEO commentary summarizing the year's progress and clinical trial updates (mitazalimab in pancreatic cancer). The structure, including detailed financial tables comparing quarterly and full-year results (2022 vs 2021), and the CEO's review of operations and financial performance, strongly indicates this is a comprehensive periodic financial report. Since the reporting period is for a full year (Jan-Dec 2022) alongside the final quarter, and it contains detailed financial statements and management discussion, it aligns best with an Annual Report (10-K) or a comprehensive Interim Report (IR). Given the inclusion of the full year's results (Jan-Dec 2022) and the depth of the financial data, it is most likely the Annual Report or a very detailed year-end Interim Report. In many jurisdictions, a document covering the full fiscal year with this level of detail is the Annual Report. However, since it explicitly covers Q4 2022 and the full year 2022, and the context suggests a focus on periodic reporting, the 'Interim / Quarterly Report' (IR) category is often used for comprehensive reports covering periods shorter than a year (like half-year reports) or year-end reports that are not explicitly the 10-K filing. Since the document covers the full year (Jan-Dec 2022) and Q4 2022, and includes the CEO's commentary and detailed financials, it is a comprehensive report. If this were a US filer, it would be a 10-K. For non-US filers presenting full-year results, 'AR' (Audit Report/Information) or 'IR' (Interim Report) are possibilities. Given the comprehensive nature covering the full fiscal year and the detailed financial tables, 'AR' (Audit Report / Information) is a strong candidate if it includes the auditor's opinion, or '10-K' if it were a US filing. Since the definitions separate '10-K' (Official yearly report) from 'AR' (Standalone audit reports), and this document contains the full financial review, '10-K' is the closest conceptual match for a full-year report, even if the company is Swedish. If we must choose between the provided codes, and recognizing it covers the full year's performance, '10-K' is the most appropriate classification for a comprehensive annual financial disclosure, although 'AR' is also plausible if it's primarily the audited statements section. Given the length and content (MD&A style commentary + full financials), I will classify it as the comprehensive annual report equivalent, '10-K', as it covers the full fiscal year (Jan-Dec 2022). Q4 2022
2023-02-10 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the period of October–December 2022 and January–December 2022, containing detailed financial statements, performance measures, CEO commentary, and operational updates. It is clearly a quarterly/interim report (Q4/Full Year) as it provides actual financial data and analysis, not just an announcement of such a report. Therefore, it fits the definition of an Interim/Quarterly Report (IR). Q4 2022
2023-02-10 English
Alligator Bioscience rapporterar positiva fas 2-data med över 50% ORR från studien OPTIMIZE-1, som utvärderar mitazalimab i bukspottskörtelcancer
Report Publication Announcement Classification · 1% confidence The document is a press release dated January 2, 2023, announcing positive interim Phase 2 data for the drug Mitazalimab in pancreatic cancer. It details clinical results (ORR of 52%), management commentary, and future plans (discussion with regulators). Crucially, the document ends with a section titled "Bifogade filer" (Attached files) containing a link to a PDF document with the same title. This structure—a brief announcement summarizing key findings and pointing to the full report—fits the definition of a Report Publication Announcement (RPA). It is not the full financial report (10-K/IR) nor a transcript (CT). Since it announces the publication of data/results, RPA is the most appropriate classification, adhering to the 'MENU VS MEAL' rule.
2023-01-02 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.